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Abstract
Background: Although the African “Fluid Expansion as Supportive therapy” (FEAST) trial showed fluid resuscitation
was harmful in children with severe febrile illness managed in resource-limited hospitals, the most recent evidence
reviewed World Health Organization (WHO) guidelines continue to recommend fluid boluses in children with shock
according to WHO criteria “WHO shock”, arguing that the numbers included in the FEAST trial were too small to
provide reasonable certainty.
Methods: We re-analysed the FEAST trial results for all international definitions for paediatric shock including
hypotensive (or decompensated shock) and the WHO criteria. In addition, we examined the clinical relevance
of the WHO criteria to published and unpublished observational studies reporting shock in resource-limited
settings.
Results: We established that hypotension was rare in children with severe febrile illness complicating only 29/
3170 trial participants (0.9%). We confirmed that fluid boluses were harmful irrespective of the definitions of
shock including the very small number with WHO shock (n = 65). In this subgroup 48% of bolus recipients
died at 48 h compared to 20% of the non-bolus control group, an increased absolute risk of 28%, but
translating to an increased relative risk of 240% (p = 0.07 (two-sided Fisher’s exact test)). Examining studies
describing the prevalence of the stringent WHO shock criteria in children presenting to hospital we found
this was rare (~ 0.1%) and in these children mortality was very high (41.5–100%).
Conclusions: The updated WHO guidelines continue to recommend boluses for a very limited number of
children presenting at hospital with the strict definition of WHO shock. Nevertheless, the 3% increased
mortality from boluses seen across FEAST trial participants would also include this subgroup of children
receiving boluses. Recommendations aiming to differentiate WHO shock from other definitions will
invariably lead to “slippage” at the bedside, with the potential of exposing a wider group of children to the
harm of fluid-bolus therapy.
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Background
In adult sepsis the primary definition of shock almost in-
variably involves hypotension as a prerequisite [1]. In chil-
dren however, the majority of paediatric guidelines do not
include hypotension as an essential criterion [2–5]. The
only exception to this are the Advanced Paediatric Life
Support (APLS) guidelines where shock is rationalised
into compensated and decompensated shock, with only
the latter characterised by the presence of hypotension [2]
(summarised in Table 1). The term “compensated shock”
is therefore more widely accepted in paediatric practice
and is synonymous with severely impaired perfusion.
Hypotension or decompensated shock is purported to be
a rare and late feature in children, and associated with a
high mortality rate. Yet, evidence to support this conten-
tion from systematic, unselected observational data from
children is lacking. Worldwide, these definitions have been
integrated into guidelines to direct acute management of
critically unwell children.
The absolute criteria defining paediatric shock vary
from guideline to guideline, and include some poorly
specified parameters, in general including similar clinical
signs of “impaired perfusion”, such as capillary refill time
(CRT), temperature gradient and assessment of pulse
volume. Whilst each of these signs are individually asso-
ciated with a poor outcome in univariate and multivari-
ate analyses, many have yet to be formally validated by
the relevant physiological studies against evidence of
macro-vascular and micro-vascular compromise [6–8].
This is particularly true of the paediatric shock definition
used by the World Health Organization (WHO), which
has been adapted from international guidelines for low-
resource hospitals, and is thus relevant to large parts of
the world [5]. For children, the criteria for WHO shock
includes the presence of all three signs of impaired per-
fusion, that is a weak and fast pulse, cool peripheries
plus a CRT >3 s. Ultimately, irrespective of the defin-
ition, identifying children with shock is the first step in
implementing immediate care, for which fluid resuscita-
tion has been the cornerstone of management.
The “Fluid Expansion as Supportive therapy” (FEAST)
trial (detailed in “Methods”) was designed to inform
guidelines on fluid resuscitation in severe febrile illness
in resource-limited settings [9]. The FEAST trial, pub-
lished in 2011, showed that fluid resuscitation was harm-
ful and led to excess mortality in all subgroups [9, 10]
and across all definitions of shock [11]. The most recent
review and the recommendations of the technical expert
group that drew up the WHO Emergency Triage and
Treatment guidelines (for resource-limited settings) in
2016 continue to recommend fluid boluses in children
with shock as defined by the WHO (“WHO shock”)
maintaining that, whilst the direction of harm was en-
tirely consistent with the overall analysis, the numbers
in this subgroup of the FEAST trial were too small to
provide reasonable certainty [12]. We therefore have
revisited the FEAST trial results and applied these to all
international definitions of paediatric shock, with critical
emphasis on WHO shock. Furthermore, since the
FEAST trial identified very few children with WHO
shock, we reviewed the applicability of the WHO shock
definition to published data from admission or emer-
gency departments reporting shock and outcome in
resource-limited hospitals.
Methods
The phase III FEAST trial was a multi-centre, random-
ized, controlled trial in 3141 children at six hospitals
Table 1 Paediatric shock definitions
Guideline Clinical definition Limitations
Advanced Paediatric Life Support
(APLS)
Compensated: normal blood pressure (BP), but
capillary refill time (CRT) >2 s, mottled, cool
peripheries, peripheral cyanosis. Decompensated:
as above but with hypotension, decreased mental status
Definition of hypotension is
separate to shock definition
Peripheral cyanosis is rare
American Academy of Critical Care
Medicine – Paediatric Advanced
Life Support (ACCM-PALS)
Clinical signs of inadequate perfusion including any of:
decreased or altered mental status; CRT >2 s (cold shock)
or flash CRT (warm shock), diminished (cold shock) or bounding
(warm shock) peripheral pulses, mottled cool extremities
(cold shock), or decreased urine output (<1 ml/kg/h)
No specific definition of
altered/decreased mental status
World Health Organization (WHO) Triad of cold hands and/or feet (temperature gradient),
CRT >3 s and weak and fast pulse
Tachycardia not defined
alongside shock definition
Fluid Expansion As A Supportive Therapy (FEAST)
study
History of fever and temperature ≥37.5 °C or <36.0 °C
and impaired consciousness (prostration or coma) and/or
respiratory distress
Stratum A (impaired perfusion)
Plus ≥1 of: CRT >2 s; lower limb temperature gradient;
weak pulse; tachycardia (defined)
Stratum B (decompensated shock)
Systolic BP <50 mmHg if < 12 months old; <60
mmHg if 1–5 years old; <70 mmHg if > 5 years old
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across East Africa, designed to assess the effects of fluid
resuscitation in critically unwell children in resource-
limited settings [9]. The FEAST trial included children
with severe febrile illness and shock. Severe febrile ill-
ness was defined as history of fever or recorded fever
with either impaired consciousness (defined as inability
to sit unsupported or inability to localise a painful
stimulus) or respiratory distress (defined as increased
work of breathing (intercostal indrawing or deep acid-
otic breathing) or both. Children with gastroenteritis, se-
vere malnutrition, burns or surgical conditions were
excluded.
The FEAST trial considered two strata for shock:
FEAST A (compensated shock) included children with
one or more of the following: CRT >2 s; lower limb
temperature gradient; weak pulse; heart rate (HR) >180
(age <12 months), >160 (age 12 months–5 years), >140
(age >5 years). FEAST B included children with decom-
pensated shock with severe hypotension (defined as sys-
tolic blood pressure (SBP) <50 mmHg if age was < 2
months; <60 mmHg if age was 1−5 years; <70 mmHg if
age was > 5 years).
The eligibility criteria for FEAST A were informed by
a critical review of international shock criteria and ap-
plied to the Kilifi Clinical Surveillance as the reference
dataset in order to inform a high-risk population for the
FEAST trial. Since 1989 the Kenya Medical Research In-
stitute (KEMRI) Programme has prospectively recorded
ward admission and discharge data using a standardised
proforma to systematically document clinical admission
data on all infants and children entering the hospital
wards. Since 2002 this has been linked to demographic
surveillance in the district [13]. For this analysis we in-
cluded over 14,000 unselected paediatric admissions
(aged over 28 days) to Kilifi District Hospital (KDH), ex-
cluding children with severe malnutrition, at the point
of triage.
First, we presented the results of the FEAST trial using
this trial definition of shock and compared this with
other international definitions of shock (Table 1). Out-
comes for those with severe hypotension (FEAST B)
were presented, but since the FEAST trial criteria for
hypotension were more stringent than other guidelines
(Additional file 1: Table S1) [2, 4], we investigated out-
come with a less strict definition (based on other inter-
national guideline criteria) and whether this could
identify a high-risk group benefiting from fluid bolus
therapy [10]. Moderately severe hypotension was there-
fore defined as SBP of 50–75, 60–75 and 70–85 mmHg,
respectively, in children aged < 12 months, 1–5 years
and > 5 years.
Second, we modeled the risk of death by 48 h after ad-
mission according to subgroups of children with the dif-
ferent combination of features of impaired perfusion and
estimated the relative risk with bolus versus no bolus
using Poisson regression (with robust standard errors).
Finally, to examine the relevance of WHO shock to
other populations we undertook a literature and narra-
tive search to identify papers reporting on WHO shock
in children presenting to hospital and their outcome.
We did not publish a protocol for the literature search
prior to conducting this review. A search of online lit-
erature was performed, including PubMed/Medline,
Global Health Library, Cochrane Database of Systematic
Reviews, Cochrane Central Register of Controlled Trials,
ClinicalTrials.gov and the WHO International Clinical
Trials Registry. There were predetermined criteria for
the eligibility of studies and data outcomes. The selec-
tion criteria included children aged 0–12 years admitted
to hospital with all or any features of shock (defined
above) and the primary outcome was mortality. English
search terms were used. We included observational and
randomised controlled trials.
Results
To identify clinical criteria determining high-risk groups
with severe febrile illness and impaired perfusion for the
future FEAST trial we initially stratified the KDH admis-
sion cohort according to clinical signs of severity (the
presence of impaired consciousness and/or increased
work of breathing). The second stratification used any
one of the three signs of severely impaired perfusion
(shock); CRT ≥3 s, weak pulse volume or a temperature
gradient (Fig. 1). First, this demonstrates that children
with any signs of clinical severity are at much higher risk
of fatal outcome. Second, children at the highest risk
were those with severity features accompanied by signs
of impaired perfusion (17% mortality). In the absence of
severity features the presence of any sign of impaired
perfusion was associated with a much lower mortality
(2.7%). These data therefore informed the inclusion cri-
teria for the FEAST trial and definitions of shock
(FEAST A).
Applying the results of the FEAST trial to all pub-
lished definitions of paediatric shock (Fig. 2) shows a re-
markable consistency of harm from bolus resuscitation,
resulting in a worse outcome compared with no-bolus
control across all definitions. Shock, as defined by the
WHO, applied to only 65 (2%) of the 3141 children in
the FEAST A stratum with 24/50 (48%) who received
boluses dying within 48 h, compared to only 3/15 (20%)
of control children - a relative risk increase of 240% (p =
0.07 (two-sided Fisher’s exact test)). The risk of death by
48 h and risk ratio for bolus versus no bolus according
to the number of features of impaired perfusion indi-
cated no evidence that excess 48-h mortality in the
FEAST trial differed with the number of signs of im-
paired perfusion (p = 0.34) (Additional file 2: Table S2).
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There was also no evidence that the excess risk of death
associated with bolus fluid differed by the presence or
absence of each individual sign (Additional file 3: Table
S3). The impact of bolus fluid within these subgroups
was consistent with the overall results of the trial.
Severe hypotension
Of the 7838 children screened, 3170 children were
enrolled into the FEAST trial (FEAST A and B), but
only 29 (0.9%) fulfilled the definition of severe
hypotension (FEAST B definition), confirming that
hypotension is rare in children with clinically defined
shock. Hypotensive shock was associated with a very
poor outcome. In the FEAST B stratum (who all re-
ceived fluid bolus therapy) the overall mortality was
62%. Of interest, only 8/29 (27.5%) hypotensive chil-
dren fulfilled the WHO shock definition and all these
participants died.
Moderately severe hypotension
Further sub-analyses were performed in children in-
cluded in the FEAST A stratum, using less stringent
criteria for moderately hypotensive children. Only 72/
3141 (2.3%) children in the FEAST A stratum fulfilled
this definition and this was associated with higher
overall mortality of 26%. Consistent with the overall
analysis, fluid bolus therapy in children with moderate
hypotension was not beneficial compared to no-bolus
controls (RR = 1.48, 95% CI 0.61–3.66, p = 0.41) but
this was not statistically significant owing to small
numbers.
Clinical relevance of WHO shock in practice?
We identified six observational studies reporting fea-
tures of paediatric shock [14–17]. Through personal
communication, we obtained a sub-analysis of two
published data sets from cohorts totaling over 20,000
children admitted to two coastal hospitals in Kenya
(Table 2). One was conducted at Coast Provincial
General Hospital incorporating 26,104 children aged
< 6 years. Only 27 children had WHO shock recorded
at admission (0.1%) and this was associated with a
high case fatality rate of 85%. The second was a re-
analysis of a larger, prospective, observational, admis-
sion dataset from KDH, from which we originally de-
rived the FEAST shock score. This included 22,911
children aged < 6 years. We found that only 33 chil-
dren fulfilled WHO shock criteria at triage (0.14%)
and this was associated a case fatality rate of 58%.
Across all of the identified databases and published
data, most reported that WHO shock was rare (~
0.1% of admissions). WHO shock was consistently as-
sociated with a very high mortality rate (41.5–100%)
in all of these study cohorts, where reported.
Discussion
To address the debate about whether children meet-
ing the FEAST trial shock or impaired perfusion cri-
teria [18–20] were relevant to other international
shock definitions, we re-analysed the FEAST trial
data. We have demonstrated that irrespective of the
definition of shock, including those with moderate
hypotension, fluid bolus therapy led to an increased
Fig. 1 Validating the FEAST trial shock criteria in a general paediatric admission cohort. *Excludes children with severe malnutrition. CRT, capillary
refill time; m, months
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risk of mortality in children with severe febrile illness
admitted to low-resource hospitals. In addition, we
were able to assess the utility of hypotension in chil-
dren with assumed septic shock as the FEAST trial
data probably represents the most comprehensive as-
sessment of this parameter since the trial permitted
the sickest children to be enrolled through a deferred
consent process [21], and as all children had meas-
urement of baseline blood pressure. We found that
only 29 children (0.9%) fulfilled the definition of se-
vere hypotension (FEAST B definition) confirming
that hypotension is rare in children with clinically
defined shock and was associated with a very poor
outcome (62% mortality among all those receiving
fluid bolus therapy) [9]. Nevertheless, this may have
been context specific in hospitals that have no formal
pre-hospital paramedic referral teams.
Three systematic reviews of fluid bolus therapy in
resource-limited hospitals have been conducted since
the publication of the FEAST trial [12, 22, 23]. Two
were conducted by the WHO guideline group [12]
and Opiyo et al. [23], and these were undertaken to
inform international and Kenyan guidelines, respect-
ively. These latter two studies included a separate
Fig. 2 Forest plot comparing outcome with fluid bolus therapy in all shock definition (using data derived from the FEAST dataset). Note: there are 16
children with missing malaria results who are not included in the calculations in children with/without malaria. 1FEAST trial criteria: history of fever or
axillary temperature >37.4 °C or <36 °C with impaired consciousness (prostration or coma) or respiratory distress, plus ≥ 1 of the following: capillary
refill time >2 s, lower limb temperature gradient, weak pulse, tachycardia (heart rate >180 beats per min (bpm) (age <12 months), >160 bpm (age 12
months−5 years), >140 bpm (age >5 years)). 2World Health Organization (WHO) Emergency Triage Assessment Treatment criteria: the presence of cold
hands or feet with capillary refill time >3 s and a weak pulse. 3American College of Critical Care Medicine (ACCM) cold shock (with two signs): axillary
temperature >37.4 °C or <36 °C plus ≥ 2 of: prostration/coma or Blantyre coma score <5, capillary refill time >2 s, weak pulse, increased temperature
gradient. 4Paediatric Advanced Life Support (PALS) (2010) compensated shock: two of the following: tachycardia (see FEAST criteria for definition),
increased temperature gradient, capillary refill time >2 s, weak pulse
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sub-analysis of the very small subgroup of children
meeting the WHO shock criteria. Owing to the small
sample size in this sub-group, and inferred “indirect-
ness” of this evidence, this resulted in strong or con-
ditional recommendations for the use of fluid
resuscitation, contrasting to the recommendations
from the systematic review by Ford et al. [22]. We
further consider these recommendations with refer-
ences to the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE)
guidance [24] which has important implications for
guideline recommendations in general that go beyond
the interpretation of the FEAST trial data.
Our first consideration is a strong practical one.
The WHO guidelines continue to advise that boluses
are useful in children with all three features of
shock, despite the evidence underpinning these rec-
ommendations having been rated as “conditional”
based on a GRADE systematic review noting a “low
quality of evidence” to support this. Our review indi-
cates that the number and thus relevance to clinical
practice of children actually fulfilling these criteria
are extremely limited. In practice, the difference be-
tween the WHO and other definitions of shock
comes down to capillary refill time (CRT) and cold
peripheries (defined as cold hands and feet rather
than temperature gradient), which have inherent dif-
ficulties in interpretation with notable inter-observer
variation in assessment [25]. The stringent analysis
of WHO shock in the FEAST data found that this
group made up only 2% of the 3141 children re-
cruited in the trial. However, they were the sickest
children, accounting for more than 9% of the deaths.
The key question is whether this group of 65 chil-
dren is big enough to provide strong evidence to
support generalisation of the trial results. There are
widely held beliefs that the strength of evidence of a
clinical trial comes only from its size. The fact is this
is not true. Strong evidence can come from smaller
trials if the underlying risk in the population is high
and the trial results in a large difference in outcome
between the treatment strategies [26]. This was case
for the group of 65 children in the FEAST trial iden-
tified by WHO criteria.
In general terms, in any clinical trial showing a dif-
ference in outcome between groups of patients given
different treatments, researchers need to be sure that
this is caused by the intervention being tested, and
Table 2 Frequency of children presenting with signs of impaired circulation or shock to hospital in low-resource settings
Reference Study design Study site Sample Inclusion criteria WHO shock and
mortality
Number with ≥ 2 signs of impaired
circulation
Tamburlini,
1999
Prospective
cohort
Brazil 3837 Children 7 days
to 5 years old presenting
to emergency room
4 (0.13%)
100%
mortality
ETAT emergency signs
(severe respiratory distress, shock,
coma/convulsions or severe
dehydration) in 98 children
Robertson,
2001
Prospective
cohort
QEQH
Blantyre,
Malawi
2281 Emergency room triage
Children aged < 5 years
Not
reported
Emergencies (n = 92);
only 7–11 had delayed
CRT (staff differed in assessments)
Ahmad,
2010
Prospective
cohort study
QECH
Blantyre,
Malawi
583 “Critically ill” children
presenting to emergency room
Did not
report WHO
shock triad
247
(42%)
Maitland,
2011
Phase III
RCT
6 hospitals
Kenya,
Uganda and
Tanzania
3141 FEAST trial inclusion
criteria
65 (2%)
41.5%
mortality
3076 (98%) by
inclusion criteria
Mbevi,
2016,
Retrospective
analysis
14 hospitals
Kenya
42,937 Admissions in children
aged > 30 days to < 5
years (excluded patients
with burns or malnutrition)
41 (0.1%)
Mortality
not reported
3219
(7.5%)a
CPGH,
2017,
unpublished
Prospective
cohort
CPGH, Mombasa,
Kenya
26,104 Admissions
<=6 years over
6 years
27
(0.1%)
85%
mortality
3403 (13.04%) –
mortality 31%
KDH,
2017,
unpublished
Prospective
cohort
KDH, Kilifi,
Kenya
22,911 Admissions
<=6 years over
6 years
33
(0.14%)
58%
mortality
9788 (42.72%) –
mortality 7.24%
ETAT Emergency Triage, Assessment And Treatment, WHO World Health Organization, CRT capillary refill time, KDH Kilifi District Hospital, CPGH Coast Provincial
General Hospital, QECH Queen Elizabeth Central Hospital
aShock-associated mortality was more broadly defined: a clinician’s indication that the child had shock as a problem accompanying diarrhoea and dehydration (an
indication of the severity of fluid loss); a diagnosis of shock associated with an underlying cause (e.g. septic shock); or use of rapid bolus fluid therapy in a child
irrespective of diagnosis
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that it is not the result of chance. Only then can the
trial result be deemed statistically significant - and
the result be generalised with a reasonable degree of
confidence. There are two inter-related factors to de-
termine this. The first is the size of the difference
between the groups or arms in the trial. The second
is the numbers of patients involved. If the difference
between arms is large, then a small number of pa-
tients are required to confirm statistical significance.
If however, the difference in outcomes is small, then
larger numbers of patients are needed.
So how does this relate to FEAST? Overall, there
was only a 3% absolute difference between the bolus
and no-bolus groups, which was statistically signifi-
cant after the fifth interim analysis when trial re-
cruitment was halted prematurely with 3141
participants enrolled [27]. The recommendation of
the data monitoring committee, at this point, was
that even if the trial recruited the projected sample
size (n = 3200), it would never be able show a bene-
fit of fluid boluses. The main result indicated a 3%
overall increase in harm associated with fluid bolus
therapy; however, relevant to WHO recent recom-
mendations, in the group of 65 children with WHO-
defined shock (a group with much higher risk of
death), the difference is stark. Almost half, 48%, of
the children given boluses died compared to 20% of
those not given boluses, an increased absolute risk of
28% [11]. As the numbers are small one cannot be
sure the 28% difference is accurate; however, as this
difference is so large, occurring across multiple cen-
tres, and is in the same direction as the main result,
one can say with a great deal of confidence that chil-
dren in the WHO group will suffer some degree of
harm from fluid boluses. Indeed, one can say with
95% confidence that the 3% increased mortality from
boluses seen across the FEAST trial can be general-
ised, and would occur if all children with WHO def-
inition shock were given boluses. This is strong
evidence of harm, even though the number of chil-
dren in the FEAST trail who satisfied the WHO def-
inition of shock is small. As indicated by Yusef et al.
“the overall trial result is usually a better guide to
the direction of effect in subgroups than the appar-
ent effect observed within a subgroup” [28].
The GRADE guideline committee suggests that
when examining the quality of evidence, inferring “in-
directness of evidence” to downgrade results should
occur only when there are substantial differences
exist between the populations. This should be sup-
ported by a plausible biological rationale that the
subgroup differs substantially from the overall trial
population. Alternatively, there is good evidence that
the effect in that sub-population is significantly dif-
ferent from the overall population [29]. Neither of
these applies to the small group with WHO shock in
the FEAST trial. Whilst the WHO guidelines have
made strong recommendations for children with
some signs of impaired perfusion, advising that they
should not receive fluid boluses (rated as a strong
level of evidence), for those with WHO shock the
updated guidelines recommended 10–20 ml of fluid
bolus over 30–60 min (with one repeat of 10 ml/kg
body weight) (Table 3). This recommendation was
rated by the technical group as conditional and based
on a low quality of evidence. In contrast, GRADE
guidance warns against strong or conditional recom-
mendations when confidence in effect estimates is
low or very low, suggesting that such recommenda-
tions are seldom justified [29].
Conclusions
The updated 2016 WHO guidelines continue to recom-
mend fluid boluses in a very rare group of children pre-
senting to hospital with severe febrile illness children,
which is complicated by the very narrow definition of
shock, despite harm being shown in this subgroup in the
FEAST trial. This group represents a very small fraction
of children admitted to hospital (less than 0.2%) who
have a very poor outcome. By maintaining strong recom-
mendations for use of boluses in this clinically irrelevant
group (< 0.2% of admissions with extremely high mortal-
ity), we are concerned that children are placed at risk of
harm from bolus therapy, with few likely to receive
benefit. Moreover, any set of guidelines that separates
the WHO shock definition from other shock definitions
will invariably lead to confusion and “slippage” at the
bedside with the potential to cause harm to a wider
group of children.
Table 3 World Health Organization Emergency Triage and Training fluid resuscitation guidelines
Definition Clinical management
Shock All of (i) cold extremities and (ii) capillary refill time
more than 3 s and (iii) weak and (iv) fast pulsea
10–20 ml/kg body weight
over 30–60 min, then a
further 10 ml/kg over 30 min
Impaired
circulation
One or two of the three features of shock,
but not the complete triad
No boluses
aNo specific values given for tachycardia ranges
WHO shock considered a Triad of signs yet the definition indicates that four features are required
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